Quick answer
Daniel Brooks is a Emerging Therapeutics Staff Writer for United States & Americas pharmaceutical intelligence editor on NovaPharmaNews, with 29 published articles covering FDA regulatory actions, clinical development, and market-moving news. Daniel Brooks focuses on next-generation therapeutics, from IND filings through early proof-of-concept studies. In 6 years covering US biotech, he has developed a strong track record in identifying programs likely to shape future standards of care.
About Daniel Brooks
Daniel Brooks focuses on next-generation therapeutics, from IND filings through early proof-of-concept studies. In 6 years covering US biotech, he has developed a strong track record in identifying programs likely to shape future standards of care.
Coverage focus
Topics and beats Daniel covers across United States & Americas.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Daniel Brooks
UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal
UCB's acquisition of Candid Therapeutics strengthens autoimmune pipeline as Two River and Vida Ventures celebrate successful exit from clinical-stage biotech.
NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment
Australia's TGA approves NIKTIMVO (axatilimab), a breakthrough first-in-class therapy for chronic graft-versus-host disease under priority review.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood cancer patients.
Oculis to Present DME Research and Pipeline Updates at ARVO 2026 Annual Meeting
Oculis will present findings from DME AWARE Delphi Study highlighting unmet needs in diabetic macular edema treatment at ARVO 2026 meeting.
Viatris Presents Six Studies on Low-Dose Estrogen Contraceptive Patch at ACOG 2026
Viatris showcases clinical data for investigational weekly contraceptive patch at American College of Obstetricians and Gynecologists meeting May 1-3.
AC Immune Advances ACI-24 Alzheimer's Trial to Final Cohort, Initiates ACI-19764 Phase 1 Study
AC Immune progresses ACI-24 Alzheimer's treatment to final trial phase while starting new brain-penetrant NLRP3 inhibitor study in Q1 2026 update.
Mabwell 9MW2821 Cervical Cancer Data to Be Presented at ESMO GC 2026 Conference
Mabwell announces presentation of clinical trial data for 9MW2821, a novel Nectin-4 targeting ADC for cervical cancer treatment at ESMO GC 2026.
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.
FDA Approval Elranatamab: Efficacy, Safety & Market Impact in RRMM
Elranatamab has gained FDA approval for relapsed/refractory multiple myeloma, showcasing promising efficacy and safety, and is set to impact the market significantly.
ANVISA Accelerated Approval: Two-Year Impact on Breakthrough Cancer Therapies
This article examines the significant effects of ANVISA's accelerated approval process on breakthrough cancer therapies, including Keytruda for melanoma and lung cancer.
ANVISA Regulatory Changes: Impact on Foreign Pharma Expedited Approvals
Discover how recent ANVISA regulatory changes affect expedited approvals for foreign pharmaceutical companies, streamlining access to essential medications.
Avicanna Welcomes U.S. Cannabis Rescheduling Decision, Advances Medical Cannabis R&D Strategy
Avicanna Inc. applauds U.S. medical cannabis rescheduling announcement, supporting the company's pharmaceutical strategy and clinical development initiatives.
AstraZeneca's BREZTRI Aerosphere Approved as First Triple Therapy for Asthma in Patients 12 and Older
AstraZeneca receives FDA approval for BREZTRI Aerosphere as the first and only triple-combination therapy for asthma maintenance treatment in patients aged 12+.
Tovecimig Shows 56% Reduction in Cancer Progression Risk in Biliary Tract Cancer Trial
Tovecimig bispecific antibody demonstrates statistically significant improvement in progression-free survival versus paclitaxel alone in Phase 2/3 trial.
Sagimet Biosciences Plans Phase 3 Denifanstat Trial for Acne Treatment in 2026
Sagimet Biosciences announces Phase 3 trial for denifanstat acne treatment starting H2 2026, while advancing TVB-3567 FASN inhibitor in Phase 1 studies.
FDA Accelerated Approval Oncology 2026: Market Analysis & Future Trends
This article delves into the FDA's Accelerated Approval pathway for oncology drugs in 2026, highlighting market dynamics and future trends in cancer treatment.
Ensartinib Phase 3 Results: Market Impact in ALK-Positive NSCLC US
The Phase 3 results of Ensartinib demonstrate promising efficacy in ALK-positive NSCLC, potentially reshaping treatment options and market dynamics in the US.
BrioHealth Solutions Receives FDA Conditional Approval for Pediatric BrioVAD Heart Device Trial
BrioHealth Solutions gets FDA conditional approval to test BrioVAD System in children with advanced heart failure through the Brio4Kids Trial study.
CGBIO Receives FDA 510(k) Clearance for EASYMADE TI Patient-Specific Titanium Implant
CGBIO becomes first Korean company to receive FDA 510(k) clearance for patient-specific titanium implant EASYMADE TI, marking regulatory milestone.
Tivic Health Rebrands as Valion Bio, Advances Entolimod for Acute Radiation Syndrome with FDA Fast Track Status
Tivic Health Systems rebrands as Valion Bio, advancing Entolimod for Acute Radiation Syndrome with FDA Fast Track and Orphan Drug designations.
OSE Immunotherapeutics' Tedopi Ovarian Cancer Trial Results Selected for ASCO 2026 Presentation
OSE Immunotherapeutics announces TEDOVA Phase 2 trial results for Tedopi in ovarian cancer will be presented at ASCO 2026, marking key milestone for immunotherapy.
Nectero Therapeutics Reports Positive Two-Year Safety Data for EAST System in Abdominal Aortic Aneurysm Trial
Nectero Therapeutics releases two-year safety and efficacy data from first-in-human trial of EAST System for small to medium abdominal aortic aneurysms.
Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11
Sanofi's Dupixent receives FDA approval as first biologic treatment for chronic spontaneous urticaria in young children, expanding pediatric treatment options.
Tempest Therapeutics Achieves Manufacturing Milestone for TPST-2003 CAR-T Cancer Treatment
Tempest Therapeutics hits key manufacturing milestone for TPST-2003 dual-targeting CAR-T therapy, supporting Q4 2026 registrational study launch.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.